Immunization Action Coalition

Home page
Pneumococcal polysaccharide vaccine (PPV23)
CDC answers your questions
 For a formatted version (PDF) of this web page, suitable for copying, click here.

The PDF version is identical to the original printed document and is suitable for making copies. Adobe Acrobat Reader
is needed  to view it. The web version  below contains the full text of this document but without the original formatting.

  

To obtain a copy of the official CDC recommendation
Prevention of Pneumococcal Disease, call (800) CDC-INFO [(800) 232-4636]
or go to ftp.cdc.gov/pub/publications/mmwr/rr/rr4608.pdf
 
William L. Atkinson, MD, MPH, medical epidemiologist, CDC's National Immunization Program, answers your questions on pneumococcal polysaccharide vaccine (PPV).

How serious is pneumococcal disease?
An estimated 40,000 cases of invasive pneumococcal disease occur annually. Case-fatality rates are high, particularly when disease results in meningitis (~30%) or bacteremia (~20%). In addition, pneumococcal pneumonia, often a secondary complication of influenza, results in an estimated 175,000 hospitalizations annually.

My patient doesn't have a record of receiving PPV, but she believes she may have had it in the past. What should I do?
Persons with uncertain or unknown vaccination status should be vaccinated.

Should all nursing home patients be vaccinated against pneumococcal disease?
Yes. Standing orders for vaccination of persons admitted to long-term care facilities can help simplify the procedure.

Should people with asthma receive PPV?
Asthma is not an indication for routine pneumococcal vaccination unless it occurs with chronic bronchitis, emphysema, or long-term systemic corticosteroid use. However, persons with obstructive lung disease should be vaccinated regardless of the cause.

My patient has had pneumococcal pneumonia. Is vaccination still necessary?
Maybe. More than 80 known serotypes of pneumococcus exist; 23 serotypes are in the current vaccine. Infection with one serotype does not necessarily produce immunity to other serotypes. Please note, however, that vaccination is indicated only for those in a risk group (click here to see table below). A history of pneumococcal pneumonia alone is not an indication for vaccination with PPV unless other risk factors are present (click here to see table below).

Should HIV-positive patients receive PPV?
Yes. Patients with HIV infection should be given PPV as soon as possible after diagnosis and a one-time revaccination dose at the appropriate interval (click here to see table below). The risk of pneumococcal infection is up to 100 times greater in HIV-infected persons than in other adults of similar age. Although severely immunocompromised persons may not respond well to the vaccine, the risk of disease is great enough to warrant vaccination even though there is a chance that the vaccine may not produce an antibody response.

If I give PPV to my patient now, must I wait a month before giving influenza or Td vaccine?
Inactivated influenza vaccine and Td toxoids may be given at the same time as or at any time before or after a dose of PPV. There are no minimum interval requirements between the doses of these or any other inactivated vaccines.

When should I vaccinate patients who are planning to have either a cochlear implant or elective splenectomy?
If time permits, give PPV to such patients at least 2 weeks before surgery.

What needle length is recommended for administration of PPV to adults?
Pneumococcal vaccine may be given either IM or SC. Use a 1–1½" needle for IM, depending on muscle mass. For SC, use a 5/8–3/4" needle.

Which patients should also receive the pneumococcal conjugated vaccine (PCV)?
PCV is recommended for all children age less than 24 months as well as children ages 24–59 months with a high-risk medical condition. Consult the ACIP recommendations for more details (MMWR, Vol. 49, RR-9, 10/6/00).
  

Immunocompetent Persons
Who needs pneumococcal (PPV) vaccine? Who in the groups in the
left column needs revaccination?
Vaccinate all persons age 65 years and older. Revaccination for healthy persons is not recommended. However, if a patient received the first dose prior to age 65, give a single revaccination at age 65 (or older) if at least 5 years have elapsed since the previous dose.
Vaccinate persons ages 2–64 years who
  • have chronic cardiovascular disease (including congestive heart failure and cardiomyopathy), chronic pulmonary disease (including COPD and emphysema), or diabetes mellitus or are cochlear implant patients.
  • have chronic liver disease (including cirrhosis), are alcoholic, or have cerebrospinal fluid leaks.
  • live in special environments or social settings (including Alaska Natives and certain American Indian populations).
If the patient received the first dose prior to age 65, give a single revaccination at age 65 (or older) if at least 5 years have elapsed since the previous dose.
Vaccinate persons ages 2–64 years with functional or anatomic asplenia (including persons with sickle cell disease or splenectomy patients). If a vaccinated patient in this risk group is older than age 10 years, give a single revaccination if at least 5 years have elapsed since the previous dose. If the patient is age 10 years or younger, consider revaccination 3 years after the previous dose.
Immunocompromised Persons
Vaccinate immunocompromised patients age 2 years and older, including those with HIV infection, leukemia, lymphoma, Hodgkin's disease, multiple myeloma, generalized malignancy, chronic renal failure (including dialysis patients), or nephrotic syndrome; those receiving immunosuppressive therapy (including long-term systemic corticosteroids); and those who have received an organ or bone marrow transplant. If a vaccinated immunocompromised patient is older than age 10 years, give a single revaccination if at least 5 years have elapsed since the previous dose. If the patient is age 10 years or younger, consider revaccination 3 years after the previous dose.
 
Item #P2015 (5/05)       
www.immunize.org/catg.d/2015pne.pdf

Home page

Immunization Action Coalition1573 Selby AvenueSt. Paul MN 55104
E-mail: admin@immunize.org Web: http://www.immunize.org/
Tel: (651) 647-9009Fax: (651) 647-9131